Search Results - "von Moos, R"

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors by Stathis, A., Hess, D., von Moos, R., Homicsko, K., Griguolo, G., Joerger, M., Mark, M., Ackermann, C. J., Allegrini, S., Catapano, C. V., Xyrafas, A., Enoiu, M., Berardi, S., Gargiulo, P., Sessa, C.

“…Summary Purpose To establish a recommended phase II dose (RP2D) for the oral smoothened inhibitor sonidegib in combination with paclitaxel; secondary…”
Get full text

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer by FÜRSTENBERGER, G, VON MOOS, R, LUCAS, R, THÜRLIMANN, B, SENN, H.-J, HAMACHER, J, BONEBERG, E.-M

“…Circulating endothelial cells (CECs) as well as bone-marrow-derived endothelial precursor cells (EPC) play an important role in neovascularisation and tumour…”
Get full text

Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia cachexia: a randomised, placebo-controlled, double-blind, double-crossover study by Strasser, F, Lutz, T A, Maeder, M T, Thuerlimann, B, Bueche, D, Tschöp, M, Kaufmann, K, Holst, B, Brändle, M, von Moos, R, Demmer, R, Cerny, T

“…Twenty-one adult patients were randomised to receive ghrelin on days 1 and 8 and placebo on days 4 and 11 or vice versa, given intravenously over a 60-min…”
Get full text

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK by Borner, M., Koeberle, D., Von Moos, R., Saletti, P., Rauch, D., Hess, V., Trojan, A., Helbling, D., Pestalozzi, B., Caspar, C., Ruhstaller, T., Roth, A., Kappeler, A., Dietrich, D., Lanz, D., Mingrone, W.

“…To determine the activity and tolerability of adding cetuximab to the oxaliplatin and capecitabine (XELOX) combination in first-line treatment of metastatic…”
Get full text

Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02) by Ruhstaller, T., Widmer, L., Schuller, J.C., Roth, A., Hess, V., Mingrone, W., von Moos, R., Borner, M., Pestalozzi, B.C., BalmerMajno, S., Köberle, D., Terraciano, L., Schnider, A., Bodis, S., Popescu, R.

“…This multicenter phase II study investigated the efficacy and feasibility of preoperative induction chemotherapy followed by chemoradiation and surgery in…”
Get full text

Cost of skeletal complications from bone metastases in six European countries by Pereira, J, Body, J-J, Gunther, O, Sleeboom, H, Hechmati, G, Maniadakis, N, Terpos, E, Acklin, Y P, Finek, J, von Moos, R

“…Objective Patients with bone metastases or lesions secondary to solid tumors or multiple myeloma often experience bone complications (skeletal-related events…”
Get more information

Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib by Cathomas, R., von Moos, R.

Get full text

Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment by Glaus, A., Boehme, Ch, Thürlimann, B., Ruhstaller, T., Hsu Schmitz, S. F., Morant, R., Senn, H. J., von Moos, R.

“…Background: Hormonal treatment for women with breast cancer is frequently proposed in the adjuvant as well as in the palliative setting. Therefore, many women…”
Get full text

Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03) by Koeberle, D, Ruhstaller, T, Jost, L, Pagani, O, Zaman, K, von Moos, R, Oehlschlegel, C, Crowe, S, Pilop, C, Thuerlimann, B

“…A sequential treatment design was chosen in this trial to ensure complete resistance to single-agent non-steroidal aromatase inhibitor (AI) and trastuzumab…”
Get full text

The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06) by Strasser, F., Blum, D., von Moos, R., Cathomas, R., Ribi, K., Aebi, S., Betticher, D., Hayoz, S., Klingbiel, D., Brauchli, P., Haefner, M., Mauri, S., Kaasa, S., Koeberle, D.

“…Patients with advanced, incurable cancer receiving anticancer treatment often experience multidimensional symptoms. We hypothesize that real-time monitoring of…”
Get full text

Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis by FÜRSTENBERGER, G, VON MOOS, R, SENN, H.-J, BONEBERG, E.-M

“…Angiogenesis is a fundamental process in tumour growth and metastatic dissemination. Possible surrogate markers for tumour angiogenesis are the amounts of…”
Get full text

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study by von Moos, R., Caspar, C.B., Thürlimann, B., Angst, R., Inauen, R., Greil, R., Bergstrom, B., Schmieding, K., Pecherstorfer, M.

“…Clinical data show that a single, 15-min i.v. infusion of ibandronate 6 mg does not significantly alter renal function. We evaluated the effect on renal…”
Get full text

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours by Del Conte, G, Sessa, C, von Moos, R, Viganò, L, Digena, T, Locatelli, A, Gallerani, E, Fasolo, A, Tessari, A, Cathomas, R, Gianni, L

“…Background: Olaparib, an oral PARP inhibitor, has shown antitumour activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian…”
Get full text

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06) by Koeberle, D., Betticher, D.C., von Moos, R., Dietrich, D., Brauchli, P., Baertschi, D., Matter, K., Winterhalder, R., Borner, M., Anchisi, S., Moosmann, P., Kollar, A., Saletti, P., Roth, A., Frueh, M., Kueng, M., Popescu, R.A., Schacher, S., Hess, V., Herrmann, R.

“…In this trial, stopping bevacizumab after completion of induction chemotherapy was associated with a shorter time to progression, but no statistically…”
Get full text

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial by Wirsching, H.-G., Tabatabai, G., Roelcke, U., Hottinger, A.F., Jörger, F., Schmid, A., Plasswilm, L., Schrimpf, D., Mancao, C., Capper, D., Conen, K., Hundsberger, T., Caparrotti, F., von Moos, R., Riklin, C., Felsberg, J., Roth, P., Jones, D.T.W., Pfister, S., Rushing, E.J., Abrey, L., Reifenberger, G., Held, L., von Deimling, A., Ochsenbein, A., Weller, M.

“…The addition of bevacizumab to temozolomide-based chemoradiotherapy (TMZ/RT → TMZ) did not prolong overall survival (OS) in patients with newly diagnosed…”
Get full text

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy by Tannock, I.F., Bouche, G., Goldstein, D.A., Goto, Y., Lichter, A.S., Prabhash, K., Ranganathan, P., Saltz, L.B., Sonke, G.S., Strohbehn, G.W., von Moos, R., Ratain, M.J.

Get full text

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16) by Metaxas, Y., Früh, M., Eboulet, E.I., Grosso, F., Pless, M., Zucali, P.A., Ceresoli, G.L., Mark, M., Schneider, M., Maconi, A., Perrino, M., Biaggi-Rudolf, C., Froesch, P., Schmid, S., Waibel, C., Appenzeller, C., Rauch, D., von Moos, R.

“…Systemic second- and third-line therapies for malignant pleural mesothelioma (MPM) result in a median progression-free survival (mPFS) of <2 months and median…”
Get full text

Quality of life in patients treated with aflibercept and FOLFIRI for metastatic colorectal cancer: interim analysis with focus on therapy lines of the non-interventional study QoLiTrap (AIO-LQ-0113) by Hofheinz, R., Scholten, F., Derigs, H., Thaler, J., von Moos, R.

Get full text

Absence of evidence is not evidence of absence: the case of non-inferiority by Klingbiel, D., Thürlimann, B., Brauchli, P., von Moos, R.

Get full text

Interim analysis of the non-interventional study QoLiTrap (AIO-LQ-0113) in patients with metastatic colorectal cancer (mCRC) treated with aflibercept (AFL) + FOLFIRI: Efficacy according to age group ≤65 and >65 years by Hofheinz, R.D., Derigs, H.-G., Piringer, G., von Moos, R.

Get full text